Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularType 2 DiabetesPhysical ActivityIssue 648

One More Study: Increasing Physical Activity Slashes CV Events and Deaths for Type 2's

Higher levels of leisure-time physical activity cut the risk of cardiovascular and all-cause mortality in people with type 2 diabetes by two-thirds.... 


The new analysis based on the Swedish National Diabetes Register (NDR) found the usual results, that physical activity is very beneficial, but in an important additional finding, researchers report that among diabetics who did little or no exercise at baseline, those who managed to substantially increase their leisure-time physical-activity levels over approximately five years cut their risk of death by almost two-thirds.

Dr. Björn Zethelius (Uppsala University, Sweden) stated at the EASD that, "We consider physical activity and dietary advice as the basal treatment for diabetes, and when it fails, different types of pharmacological treatment are added." "But what this study shows is that it's never too late to increase your physical activity. Even when you are on medication, if you increase your physical activity, you will lower your risk for cardiovascular diseases. I think that's the important message."

Zethelius and colleagues used data on leisure-time physical activity, recorded yearly, from the more than 15,000 men and women with type 2 diabetes in the NDR. Participants were grouped as either "low physical activity" (no regular exercise or exercise once per week) or "regular exercise" (between three times per week and daily exercise). If patients died during the course of the study, their last recorded physical-activity level was used for the analysis.

Over a five-year period, regular exercisers were significantly less likely to have a cardiovascular event or to die either from cardiovascular disease or any other cause.

Investigators also looked at diabetics who reported doing little or no physical activity at baseline but who managed to increase their regular exercise to at least three times per week by the end of the study period (a mean of 4.8 years).

Here the reduction in study end points was even more striking, with the number of cardiovascular deaths among diabetics who increased their exercise levels dropping by 67% as compared with subjects who did not improve their exercise habits. Rates of all-cause mortality, likewise, were reduced by almost the same degree.

End point

Persistent low exercise vs increasing exercise over study

Fatal/nonfatal CHD
0.41 (0.30-0.54)
Fatal/nonfatal CVD
0.79 (0.69-0.92)
Fatal CVD
0.32 (0.17-0.60)
All-cause mortality
0.35 (0.25-0.49)

*Adjusted for age, gender, diabetes duration, type of hypoglycemic treatment, smoking, body-mass index, systolic blood pressure, HbA1c, LDL, HDL, triglycerides, and albuminuria

Similar reductions were seen when the "increasing-exercise" group was combined with the "regular-exercise" group.

The Swedish findings echo those of a recent German study and meta-analysis, conducted in a mixed cohort of people with type 1 and 2 diabetes. A strength of this latest study, Zethelius stressed, is the extent to which it took conventional cardiovascular risk factors into account.

The data is epidemiological, not interventional, so it's not clear whether the same results would be seen in practice, but the reductions are nevertheless "impressive," Zethelius said.

Exercise interventions are typically considered to be even harder in diabetic patients than in the general CV-prevention population, but Zethelius points out that approximately 1,800 patients, or one in five, moved from a low physical-activity category into a higher physical-activity bracket over the course of the study.

As to whether it is physicians failing to recommend physical activity in their patients, Zethelius believes this is "more of a culture question. . . . I'm just speculating, but I think that may be different in different countries."

The program moderator Dr. Nick Wareham (Institute of Metabolic Science, Cambridge, UK) stressed that the data should serve as a wake-up call to physicians. "These data should encourage us to focus on encouraging physical activity as part and parcel of medical care. Not only are there benefits potentially in terms of cardiovascular risk, but also for other end points such as all-cause mortality and cancer."

Randomized clinical trials looking at hard cardiovascular end points in diabetes patients "are probably never going to be done," Wareham noted. "We do have to rely on this sort of observational data, but it does encourage us to put promotion of physical activity as central to our care. Just the very fact of making people aware of just how little they're doing, that's one thing. If you provide a pedometer to patients and encourage them to measure and be aware of their own inactivity, that's been shown to increase activity. We need to use as many tactics as we can."

Zethelius B, Gudbjörnsdottir S, Eeg-Olofsson L, et al. Leisure time physical activity and risks of cardiovascular disease and mortality in type 2 diabetes: Report from the Swedish National Diabetes Register. European Association for the Study of Diabetes 2012 Meeting; October 2, 2012; Berlin, Germany. Presentation 54. 



Bookmark and Share | Print | Category | Home

This article originally posted 18 October, 2012 and appeared in  CardiovascularType 2 DiabetesPhysical ActivityIssue 648

Past five issues: Issue 796 | Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 | Diabetes Clinical Mastery Series Issue 254 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
Two New Possible Methods for Diagnosing and Monitoring Diabetes
Posted August 07, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015
A Telltale Sign of Type 2 Diabetes
Posted August 07, 2015

Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients have reached goal for A1c, BP and cholesterol?

CME/CE of the Week
Deepak Bhatt, MD, MPH, and Jeffrey J. Popma, MD

Category: Cardiology